Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALDX Aldeyra Therapeutics

Trading 07-21 13:02:11 EDT

1.77

+0.07

+3.82%

High1.77	Low1.69	Vol424.83K
Open1.71	D1 Closing1.70	Amplitude4.41%
Mkt Cap106.19M	Tradable Cap92.97M	Total Shares60.16M
T/O736.67K	T/O Rate0.81%	Tradable Shares52.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALDX","market":"US","secType":"STK","nameCN":"Aldeyra Therapeutics","latestPrice":1.765,"timestamp":1784653300391,"preClose":1.7,"halted":0,"volume":424825,"delay":0,"changeRate":0.03823529411764703,"floatShares":52675600,"shares":60162773,"eps":-0.454915,"marketStatus":"Trading","change":0.065,"latestTime":"07-21 13:02:11 EDT","open":1.71,"high":1.765,"low":1.69,"amount":736672.4643250001,"amplitude":0.044118,"askPrice":1.77,"askSize":1972,"bidPrice":1.76,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.454915,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784664000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1399003200000,"exchange":"NASDAQ","adjPreClose":1.7,"preHourTrading":{"tag":"盘前","latestPrice":1.7389,"preClose":1.7,"latestTime":"06:25 EDT","volume":309,"amount":539.4399018,"timestamp":1784629519708,"change":0.0389,"changeRate":0.022882,"amplitude":0.062765},"postHourTrading":{"tag":"盘后","latestPrice":1.72,"preClose":1.7,"latestTime":"19:34 EDT","volume":1190,"amount":2025.546,"timestamp":1784590449219,"change":0.02,"changeRate":0.011765,"amplitude":0.011765},"volumeRatio":0.584881,"impliedVol":3.1618,"impliedVolPercentile":0.8247},"requestUrl":"/m/hq/s/ALDX","defaultTab":"news","newsList":[{"id":"2651445490","title":"Aldeyra Therapeutics Seeks FDA Clarification on Reproxalap NDA Meeting Minutes","url":"https://stock-news.laohu8.com/highlight/detail?id=2651445490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651445490?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:44","pubTimestamp":1784198647,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics (ALDX) said Thursday it received meeting minutes from the US Food and Drug Administration regarding the potential resubmission of its new drug application for reproxalap to treat ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","LABU","ALDX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651496271","title":"Aldeyra Therapeutics - to Request FDA Type D Meeting on Nda of Reproxalap Resubmission by End of Q3 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2651496271","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651496271?lang=en_us&edition=fundamental","pubTime":"2026-07-16 04:59","pubTimestamp":1784149153,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H1CR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649607056","title":"Levicept Appoints Darlene Deptula-hicks as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2649607056","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649607056?lang=en_us&edition=fundamental","pubTime":"2026-07-07 16:00","pubTimestamp":1783411200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA2TFNVJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642923140","title":"Aldeyra Therapeutics director Darlene Deptula-Hicks files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642923140","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642923140?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:13","pubTimestamp":1781208828,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics director Darlene Deptula-Hicks filed an initial Form 3 on June 11, dated June 9.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLbbh3W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642415216","title":"Aldeyra Therapeutics appoints Darlene Deptula-Hicks to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642415216","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642415216?lang=en_us&edition=fundamental","pubTime":"2026-06-10 08:30","pubTimestamp":1781051414,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics named Darlene Deptula-Hicks to its board as it moves toward potential commercialization of its immune-mediated disease pipeline.Deptula-Hicks is acting CFO at Normunity, a clinical-stage cancer biotech.She previously served as CFO of F-star Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL7Lqcdx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BZ08YS42.EUR","ALDX","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515","01177","IE00BZ08YT58.USD","BK1521","BK1589","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642250415","title":"Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642250415","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642250415?lang=en_us&edition=fundamental","pubTime":"2026-06-10 08:30","pubTimestamp":1781051400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUA3MF4XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641257091","title":"Top Executive Makes Bold Insider Move at Aldeyra Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2641257091","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641257091?lang=en_us&edition=fundamental","pubTime":"2026-06-06 10:07","pubTimestamp":1780711641,"startTime":"0","endTime":"0","summary":"New insider activity at Aldeyra Therapeutics ( ($ALDX) ) has taken place on June 5, 2026. Aldeyra Therapeutics has caught investors’ attention afte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-bold-insider-move-at-aldeyra-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executive-makes-bold-insider-move-at-aldeyra-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641477011","title":"Aldeyra Therapeutics CEO Todd C. Brady acquires 250,000 common shares worth $418,450","url":"https://stock-news.laohu8.com/highlight/detail?id=2641477011","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641477011?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:20","pubTimestamp":1780690806,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics President and CEO Todd C. Brady bought 250,000 common shares in open-market transactions.The purchases were priced at a weighted average of $1.67 per share.Brady’s direct holding rose to 1,721,298 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL608xrB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aldeyra Therapeutics CEO Todd C. Brady acquires 250,000 common shares worth $418,450","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641161347","title":"3 Promising Penny Stocks With Market Caps Reaching $300M","url":"https://stock-news.laohu8.com/highlight/detail?id=2641161347","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641161347?lang=en_us&edition=fundamental","pubTime":"2026-06-05 01:07","pubTimestamp":1780592866,"startTime":"0","endTime":"0","summary":"The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can still open doors to growth opportunities, typically in smaller or newer companies. We've identified three penny stocks that combine balance sheet strength with potential for outsized gains, giving investors the chance to discover hidden value in quality companies.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3052000-choice2-main-header/1585186800829","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3052000-choice2-main-header/1585186800829"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nasdaq-bwen/broadwind/news/3-promising-penny-stocks-with-market-caps-reaching-300m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nasdaq-bwen/broadwind/news/3-promising-penny-stocks-with-market-caps-reaching-300m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4509","ALDX","HK0000252160.HKD","HK0000252152.HKD","BK4077","BK4539","HK0000500386.USD","BK4139","ZH","BWEN","BK4182"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640178599","title":"Aldeyra Therapeutics CEO joins Jefferies Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2640178599","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640178599?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:03","pubTimestamp":1780398235,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics CEO Todd C. Brady will join a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026.The session is scheduled to start at 8:45 a.m. ET in New York.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on June 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7S7lN9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638506471","title":"Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2638506471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638506471?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:59","pubTimestamp":1779875996,"startTime":"0","endTime":"0","summary":"A class action lawsuit was filed against Aldeyra Therapeutics ($ALDX) on March 30, 2026. Plaintiffs in the federal securities lawsuit allege that t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/shareholders-sue-aldeyra-therapeutics-over-dry-eye-drug-claims?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/shareholders-sue-aldeyra-therapeutics-over-dry-eye-drug-claims?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635228098","title":"Aldeyra Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635228098","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635228098?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:01","pubTimestamp":1778619709,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAldeyra Therapeutics Inc ALDX.OQ reported a quarterly adjusted loss of 6 cents per share for the quarter ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P379:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634983134","title":"Aldeyra Therapeutics Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634983134","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634983134?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:40","pubTimestamp":1778280020,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc  expected to post a loss of13cents a share - Earnings Preview Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631682969","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2631682969","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631682969?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:00","pubTimestamp":1777543200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A. O. Smith Corp                                 1Q       .94    6:55 AM. ·Air Prod & Chem                                  2Q      3.06    6:00 AM. ·Altria Grp Inc                                    1Q      1.25    7:00 AM. ·APi Grp Corp                                     1Q       .30    7:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAND","BOOM","BIO.B","BAX","ALEC","ALDX","BBIO","ANGX","ASUR","ARDX","AXTI","BFLY","ACA","ATI","CAH","ASND","AUPH","BBVA","AVTX","AES","AMGN","ALNY","BC","BZH","AUTL","AEM","AME","ALHC","ARVN","AIG","AOS","ATR","BMY","BR","AX","AJG","BDC","AXTA","BLDR","ADT","APG","APLS","CABO","BSAC","APD","ACCO","BCYC","AIN","AAPL","BIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631542057","title":"3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631542057","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631542057?lang=en_us&edition=fundamental","pubTime":"2026-04-30 01:08","pubTimestamp":1777482486,"startTime":"0","endTime":"0","summary":"The United States market has remained flat over the last week but has seen a significant rise of 29% over the past 12 months, with earnings forecasted to grow by 16% annually. In this context, identifying stocks that are trading below their intrinsic value can present compelling opportunities for investors seeking to capitalize on potential growth while navigating current market conditions.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/7013000-choice1-main-header/1585186561056","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7013000-choice1-main-header/1585186561056"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/banks/nasdaq-cvbf/cvb-financial/news/3-stocks-estimated-to-be-trading-below-intrinsic-value-by-up-11","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/banks/nasdaq-cvbf/cvb-financial/news/3-stocks-estimated-to-be-trading-below-intrinsic-value-by-up-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7129","LU0109394709.USD","SG9999001440.SGD","KMB","MRDN","BK4548","BK4130","ALNY","BK4085","BK4139","BK4150","LU1861220207.SGD","LU0320765992.SGD","RHI","ALDX","LU0054578231.USD","BK4211","BK4585","SGHC","LU1430594728.SGD","LU1878469433.USD","LU1861217088.USD","MC","LU1571399168.USD","LOB","BK4127","LU2463526074.USD","LU0882574055.USD","BUSE","LU0114720955.EUR","RHI.AU","BK4588","OUST","PTRN","BK4018","CVBF","BK4220","BK4533","GLNG","LU0889565916.HKD","BK4567","BK4157","BK4504","LU1585245621.USD","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630173233","title":"Aldeyra Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630173233","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630173233?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:11","pubTimestamp":1777320710,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics will hold its annual stockholder meeting in Boston on June 9, 2026.Stockholders will vote on election of Todd C. Brady as Class III director to serve until 2029.Advisory vote scheduled on compensation for named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL6cyxPk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630319727","title":"April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2630319727","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630319727?lang=en_us&edition=fundamental","pubTime":"2026-04-28 01:08","pubTimestamp":1777309715,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 30% increase over the past year with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be trading below their estimated fair value can present opportunities for investors seeking potential long-term gains.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/april-2026s-top-3-stocks-that-may-be-trading-below-estimated","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/april-2026s-top-3-stocks-that-may-be-trading-below-estimated","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","LU0109394709.USD","LU0114720955.EUR","GLNG","BK4585","BK4211","FBK","ASIC","BK4183","ALDX","CCB","BK4144","LU2065731478.USD","LU0889565916.HKD","ALNY","OBK","BK4107","BK4139","GKOS","LU0320765992.SGD","BK4097","IE0009354923.USD","LU0882574055.USD","BK4548","LU1878469433.USD","ZYME","FRME","BK4082","BHST","BUSE","ALLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629024990","title":"Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2629024990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629024990?lang=en_us&edition=fundamental","pubTime":"2026-04-23 02:32","pubTimestamp":1776882741,"startTime":"0","endTime":"0","summary":"Aldeyra (ALDX) said its dry eye drug reproxalap had demonstrated broad-based, rapid-onset activity, consistent safety, and statistically significan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/aldeyra-therapeutics-faces-securities-lawsuit-over-reproxalap-trial-disclosures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/aldeyra-therapeutics-faces-securities-lawsuit-over-reproxalap-trial-disclosures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALDX","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629715067","title":"Aldeyra Therapeutics Announces Upcoming Board Member Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=2629715067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629715067?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:38","pubTimestamp":1776721083,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics ( ($ALDX) ) just unveiled an update. On April 20, 2026, Aldeyra Therapeutics, Inc. announced that Board member Martin J. Joyce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aldeyra-therapeutics-announces-upcoming-board-member-departure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aldeyra-therapeutics-announces-upcoming-board-member-departure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629573779","title":"Aldeyra director Martin Joyce will not stand for re-election at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629573779","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629573779?lang=en_us&edition=fundamental","pubTime":"2026-04-21 05:01","pubTimestamp":1776718886,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics director Martin J. Joyce decided not to stand for re-election at 2026 annual meeting of stockholders.Joyce will remain on board until his term expires at 2026 annual meeting.Decision was not tied to any disagreement with Aldeyra.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLb3GNgZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aldeyra.com;ir.aldeyra.com","stockEarnings":[{"period":"1week","weight":-0.1192},{"period":"1month","weight":-0.1327},{"period":"3month","weight":0.0119},{"period":"6month","weight":-0.6593},{"period":"1year","weight":-0.6846},{"period":"ytd","weight":-0.6718}],"compareEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":-0.0062},{"period":"3month","weight":0.054},{"period":"6month","weight":0.0827},{"period":"1year","weight":0.1825},{"period":"ytd","weight":0.0882}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.071524},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.000501},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.048652},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.015598},{"month":5,"riseRate":0.416667,"avgChangeRate":0.023947},{"month":6,"riseRate":0.384615,"avgChangeRate":0.046727},{"month":7,"riseRate":0.538462,"avgChangeRate":0.032994},{"month":8,"riseRate":0.5,"avgChangeRate":0.050447},{"month":9,"riseRate":0.5,"avgChangeRate":0.169785},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.091942},{"month":11,"riseRate":0.666667,"avgChangeRate":0.079554},{"month":12,"riseRate":0.416667,"avgChangeRate":-0.031913}],"exchange":"NASDAQ","name":"Aldeyra Therapeutics","nameEN":"Aldeyra Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aldeyra Therapeutics,ALDX,Aldeyra Therapeutics股票,Aldeyra Therapeutics股票老虎,Aldeyra Therapeutics股票老虎国际,Aldeyra Therapeutics行情,Aldeyra Therapeutics股票行情,Aldeyra Therapeutics股价,Aldeyra Therapeutics股市,Aldeyra Therapeutics股票价格,Aldeyra Therapeutics股票交易,Aldeyra Therapeutics股票购买,Aldeyra Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction